Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Breast Cancer Detection Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Prospector who wrote (12)	10/25/1998 7:49:00 PM
From: M&A West, Inc.	Respond to of 40

LIFELINE BIOTECHNOLOGIES BEGINS MULTI-CENTER STUDY FOR ITS BREAST CANCER >DETECTION PRODUCT, FIRST WARNING™ > >Reno, Nevada—October 26, 1998—Lifeline BioTechnologies, Inc., (OTC BB:LBTI) >has just received approval and verification of its clinical protocol to >study 1200 women with the First Warning™ system. > >The study will be directed by Dr. Martin Laguens, who is a qualified medical >investigator and is a board certified Anatomopathologist as well as >Dermatopathologist. Dr. Laguens has conducted several studies for American >medical companies. He will direct Lifeline's mutli-center study in Buenos >Aires and La Plata, Argentina. > >The company chose this area because of the large number of unscreened female >patients available for study through government medical programs as well as >the high quality of Argentina's medical delivery system. > >The protocol is divided into three parts. One study group will be women >referred to the breast clinic for clinical study because of existing >problems. A second group will be women recommended for surgical biopsy. >The third group will be women who have never been screened for breast >cancer. > >The study start date is expected near term. > >Lifeline BioTechnologies, Inc.'s (Lifeline) has developed a non-invasive >test for early breast cancer detection. The test is incorporated into a >proprietary product called First Warning ™. In preliminary pilot studies, >First Warning ™ demonstrated great promise in detecting formation of >extremely early stage breast lesions, particularly in younger women. >Management believes the product is an alternative to other breast cancer >detection products, including technology from Trex Medical Corporation >(Amex: TXM) and Computerized Thermal Imaging, Inc. (OTC BB:COII). > > The second product division under Lifeline BioTechnologies is a line of >nutritional food supplements packaged and sold under the tradename NATURE'S >CREATIONS. These supplements are marketed and directed towards people >afflicted with degenerative diseases that are commonly found in the aging >population. These diseases include cancer (breast, colon and prostate) >cardiovascular, osteoporosis and mental alertness. > >For more information on Lifeline BioTechnologies, please visit, >www.lbti.com. > >Financial Statements in this press release (if any) other than historical >facts are "forward-looking" statements with the meaning of section 27A of >the Securities Act of 1933, section 21E of the Securities Exchange Act of >1934, and as that term is defined in the Private Securities Litigation >Reform Act of 1995. The Company intends that such statements about the >Company's future expectations, including future revenues and earnings, and >all other forward-looking statements be subject to the safe harbors created >thereby. Since these statements (future operational results and sales) >involve risks and uncertainties and are subject to change at any time, the >Company's actual results could differ materially from expected results. > >Contact: >M&A West, Inc. (Investor Relations) >Scott Kelly >650-588-2678 >www.mawest.com

To: Prospector who wrote (12)	11/5/1998 7:13:00 PM
From: Prospector	Read Replies (1) \| Respond to of 40

CTI Demands LifeLine BioTechnologies Cease Unauthorized Use of CTI's Name in All Communications With Wall Street, the Media and the Industry OGDEN, Utah, Nov. 5 /PRNewswire/ -- Computerized Thermal Imaging, Inc. (OTC Bulletin Board: COII - news; CTI), a leader in the development of thermal imaging for the diagnosis of malignant breast cancer tumors, said today that its general counsel has sent a formal request to the management of LifeLine BioTechnologies demanding that LifeLine cease using CTI's name in its press releases, conference calls and other communications with the investment community and public at large. CTI's president, David A. Packer said, "There have been a number of instances in which LifeLine has used our Company's name in its press releases without our consent. LifeLine seems to be trying to take advantage of our good name, reputation and our leading role in the development of breast cancer detection technology to expand the visibility of their company and its food supplement products by deliberately manipulating the Internet news delivery mechanisms by referencing CTI's breast cancer technology. Their actions have created confusion and conveyed a false impression to some that we have somehow aligned ourselves with this nutritional food company. Nothing could be further from the truth." "In addition, LifeLine made statements regarding CTI and our technology in their recent conference call that were false and misleading. They claim to be an alternative to CTI while their statements make it clear that they have little or no knowledge of us, our technology or our advanced stage of product development and approval. We have therefore informed the management of LifeLine and its public relations firm to immediately cease the unauthorized use of CTI's name in any public communications. In the event that LifeLine fails to comply with our request, we intend to take legal action,'' Packer added. CTI's technology uses a sophisticated heat sensitive camera to record an image of heat waves produced by breast tissue. This image is processed by a proprietary computer program that is designed to recognize and differentiate the distinct heat signatures of malignant and benign breast tumors. The procedure is painless and requires no exposure to radiation or breast compression. Clinical trials are currently underway at a number of leading cancer research centers and hospitals. Computerized Thermal Imaging, Inc. develops and deploys thermal imaging and associated technologies for use in the enhancement of medical screening, diagnosis and patient management. More information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at 801-776-4700. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to technical risks associated with new technology development, government regulatory approvals or continued working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC. SOURCE: Computerized Thermal Imaging, Inc. [BACK]